|Day Low/High||63.06 / 63.91|
|52 Wk Low/High||55.13 / 70.90|
At CES 2017, SleepScore Labs shared exciting new information that will change the way people think about their sleep.
ResMed (RMD) reported earnings and revenue that fell short of analysts' expectations for the 2017 fiscal first quarter.
Dr. Oz and ResMed to Release Results of National Sleep Study, Live, January 6th
The S+ by ResMed is a consumer device to raise awareness of users' sleep habits, giving them the ability to understand, track, and optimize their sleep
Cramer is concerned about Dave & Buster's but says Chipotle's problems are behind it.
When it comes to stock prices, competition has a lot of influence, Cramer says.
Today ResMed welcomed positive results from the independent Home Oxygen Therapy- Home Mechanical Ventilation (HOT-HMV) study 1 regarding the benefits of home non-invasive ventilation (NIV).
The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 1,147,291 share increase in total short interest for ResMed Inc. , to 12,554,278, an increase of 10.06% since 07/29/2016.
Jefferies reduced its rating on ResMed (RMD) stock to 'underperform' from 'hold' on Tuesday.
Here are Tuesday's top research calls, including an upgrade for Square and new coverage of Chipotle Mexican Grill, Darden Restaurants and McDonald's.
Trade-Ideas LLC identified ResMed (RMD) as a post-market laggard candidate
Stocks with insider trader activity include MTSI, DXCM and RMD
Top-line results from ResMed-sponsored CAT-HF study announced at 2016 annual Heart Failure Congress
Trade-Ideas LLC identified ResMed (RMD) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Trade-Ideas LLC identified ResMed (RMD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Here are Wednesday's top research calls, including downgrades for Apple, Twitter and Xerox, and an upgrade for JetBlue.
Shares of the maker of sleep-apnea devices are poised to rise and shine.
ResMed (RMD) stock coverage was reinstated with an ‘underweight’ rating and $55 price target at Barclays on Thursday morning.
The most recent short interest data has been released by the NASDAQ for the 03/15/2016 settlement date, which shows a 2,157,595 share decrease in total short interest for ResMed Inc. , to 10,061,207, a decrease of 17.66% since 03/01/2016.
Stocks with insider trader activity include SNAK, PCLN and RMD
TheStreet highlights 3 stocks pushing the health services industry lower today.
These stocks are within range of triggering big breakouts. Here's how to trade them now.
Stocks with insider trader activity include GENC, LPLA and RMD
Stocks with insider trader activity include IPWR, GLAD and RMD
These stocks trading on unusual volume are within range of triggering breakout trades.
Trade-Ideas LLC identified ResMed (RMD) as a post-market leader candidate
Barclays downgraded ResMed (RMD) and lowered its price target on the stock on Tuesday.
Here are Tuesday's top research calls, including upgrades for Campbell Soup and Lennar, and downgrades for Express Scripts and Dunkin' Brands.